[email protected] +1 646 480 7505 (U.S.) | +44 203 318 2846 (U.K.)

TABLE  OF CONTENTS

1          Introduction

1.1       Market Definition

1.2       Market Scope

2          Research Methodology

2.1       Primary Research

2.2       Research Methodology

2.3       Assumptions & Exclusions

2.4       Secondary Data Sources

3          Market Overview

3.1       Report Segmentation & Scope

3.2       Value Chain Analysis: Overactive Bladder Treatment Market

3.3       Key Market Trends

3.3.1    Drivers

3.3.2    Restraints

3.3.3    Opportunities

3.4       Porter’s Five Forces Analysis

3.4.1    Bargaining Power of Suppliers

3.4.2    Bargaining Power of Buyers

3.4.3    Threat of Substitution

3.4.4    Threat of New Entrants

3.4.5    Competitive Rivalry

3.5       Market Share Analysis

4          Pharmacotherapy Overview

4.1       Introduction

4.1.1    Market Size & Forecast

4.2       Anticholinergics

4.2.1    Market Size & Forecast

4.2.2    Solifenacin

4.2.3    Oxybutynin

4.2.4    Fesoterodine

4.2.5    Darifenacin

4.2.6    Tolterodine

4.2.7    Trospium

4.2.8    Other Anticholinergics

4.3       Mirabegron

4.3.1    Market Size & Forecast

4.4       Botox

4.4.1    Market Size & Forecast

4.5       Neurostimulation

4.5.1    Market Size & Forecast

4.6       Intravesical Instillation

4.6.1    Market Size & Forecast

5          Disease Overview

5.1       Introduction

5.1.1    Market Size & Forecast

5.2       Idiopathic Overactive Bladder

5.2.1    Market Size & Forecast

5.3       Neurogenic Overactive Bladder

5.3.1    Market Size & Forecast

5.3.2    Overactive Bladder in Parkinson's Disease

5.3.3    Overactive Bladder in Stroke

5.3.4    Overactive Bladder in Multiple Sclerosis

5.3.5    Overactive Bladder in Spinal Cord Injury

5.3.6    Overactive Bladder in Other Disorders  

6          Regional Overview

6.1       Introduction

6.1.1    Market Size & Forecast

6.2       America

6.2.1    North America

6.2.1.1 U.S.

6.2.1.1.1          By Pharmacotherapy

6.2.1.1.2          By Disease

6.2.1.2 Canada

6.2.1.2.1          By Pharmacotherapy

6.2.1.2.2          By Disease

6.2.1.3 Mexico

6.2.1.3.1          By Pharmacotherapy

6.2.1.3.2          By Disease

6.2.2    Latin America

6.2.2.1 By Pharmacotherapy

6.2.2.2 By Disease

6.3       Europe

6.3.1    Market Size & Forecast

6.3.2    Germany

6.3.2.1 By Pharmacotherapy

6.3.2.2 By Disease

6.3.3    France

6.3.3.1 By Pharmacotherapy

6.3.3.2 By Disease

6.3.4    U.K.

6.3.4.1 By Pharmacotherapy

6.3.4.2 By Disease

6.3.5    Italy

6.3.5.1 By Pharmacotherapy

6.3.5.2 By Disease

6.3.7    Spain

6.3.6.1 By Pharmacotherapy

6.3.6.2 By Disease

6.3.6    Rest of Europe

6.3.7.1 By Pharmacotherapy

6.3.7.2 By Disease 

6.4       Asia Pacific

6.4.1    Market Size & Forecast

6.4.2    Japan

6.4.2.1 By Pharmacotherapy

6.4.2.2 By Disease

6.4.3    China

6.4.3.1 By Pharmacotherapy

6.4.3.2 By Disease

6.4.4    Australia

6.4.4.1 By Pharmacotherapy

6.4.4.2 By Disease

6.4.5    India

6.4.5.1 By Pharmacotherapy

6.4.5.2 By Disease

6.4.6    South Korea

6.4.6.1 By Pharmacotherapy

6.4.6.2 By Disease

6.4.7    Rest of Asia-Pacific

6.4.7.1 By Pharmacotherapy

6.4.7.2 By Disease

6.5       Middle East & Africa

6.5.1    Market Size & Forecast

6.5.2    Saudi Arabia

6.5.2.1 By Pharmacotherapy

6.5.2.2 By Disease

6.5.3    South Africa

6.5.3.1 By Pharmacotherapy

6.5.3.2 By Disease

6.5.4    Brazil

6.5.4.1 By Pharmacotherapy

6.5.4.2 By Disease

6.5.5    Rest of Middle East & Africa

6.5.5.1 By Pharmacotherapy

6.5.5.2 By Disease

7          Company Profile

7.1       Teva Pharmaceutical Industries Limited

7.1.1    Company Overview

7.1.2    Financial Performance

7.1.3    Recent Developments

7.1.4    Product Portfolio

7.2       Allergan, PLC.

7.2.1    Company Overview

7.2.2    Financial Performance

7.2.3    Recent Developments

7.2.4    Product Portfolio

7.3       Astellas Pharma Inc.

7.3.1    Company Overview

7.3.2    Financial Performance

7.3.3    Recent Developments

7.3.4    Product Portfolio

7.4       Pfizer, Inc.

7.4.1    Company Overview

7.4.2    Financial Performance

7.4.3    Recent Developments

7.4.4    Product Portfolio

7.5       Mylan N.V.

7.5.1    Company Overview

7.5.2    Financial Performance

7.5.3    Recent Developments

7.5.4    Product Portfolio

7.6       Endo International PLC

7.6.1    Company Overview

7.6.2    Financial Performance

7.6.3    Recent Developments

7.6.4    Product Portfolio

7.7       Cogentix Medical, Inc.

7.7.1    Company Overview

7.7.2    Financial Performance

7.7.3    Recent Developments

7.7.4    Product Portfolio

7.8       Aurobindo Pharma Limited

7.8.1    Company Overview

7.8.2    Financial Performance

7.8.3    Recent Developments

7.8.4    Product Portfolio

7.9       Endo International PLC

7.9.1    Company Overview

7.9.2    Financial Performance

7.9.3    Recent Developments

7.9.4    Product Portfolio

7.10     Sanofi

7.10.1  Company Overview

7.10.2  Financial Performance

7.10.3  Recent Developments

7.10.4  Product Portfolio



Request For Free Sample
Choose license Type

Buy Chapters or Sections

Avail customized purchase option to meet your exact research needs:

1)Buy sections of the report
2)Buy country level report
3)Request for historical data

Request a Free Sample   Special Pricing
Related Reports